Infliximab for reversible dementia in acute onset of neuro-Behçet's disease: A case report and cytokine analysis

Keisuke Imabayashi, Masahiro Ayano, Kazuhiko Higashioka, Kana Yokoyama, Ken Yamamoto, Koji Takayama, Hiroki Mitoma, Yasutaka Kimoto, Mitsuteru Akahoshi, Yojiro Arinobu, Koichi Akashi, Takahiko Horiuchi, Hiroaki Niiro

Research output: Contribution to journalArticlepeer-review

Abstract

We describe a 49-year-old female patient with neuro-Behçet's disease (NBD) with acute onset of fever and symptoms of dementia. High-dose glucocorticoid was partially effective for cognitive impairment, and infliximab, an anti-TNF-α antibody, gradually improved the symptoms. An analysis of cytokines showed that IP-10 in the cerebrospinal fluid was higher than that in the peripheral blood, and both decreased after treatment. This is the first known case of NBD wherein the patient with acute onset of dementia responded to a treatment with infliximab. In glucocorticoid-resistant patients, it is important to consider the introduction of infliximab to prevent irreversible brain dysfunction.

Original languageEnglish
Article number577631
JournalJournal of Neuroimmunology
Volume357
DOIs
Publication statusPublished - Aug 15 2021

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology
  • Neurology
  • Clinical Neurology

Fingerprint

Dive into the research topics of 'Infliximab for reversible dementia in acute onset of neuro-Behçet's disease: A case report and cytokine analysis'. Together they form a unique fingerprint.

Cite this